Healthcare Supplies

Eli Lilly's Zepbound Shows Promise in Heart Failure Patients

Eli Lilly's Zepbound & Novo Nordisk's Wegovy show health benefits beyond weight loss, influencing investment strategies in pharmaceutical stocks.

AbbVie Stock in Focus with Strategic Cerevel Acquisition

AbbVie (ABBV) acquires Cerevel, enhancing its drug portfolio and opening new growth avenues in neuroscience for investors in ABBV stock.

BAYRY Stock: Bayer Faces Major Legal and Drug Dev Setbacks

Bayer's legal and pharmaceutical setbacks are something investors should pay attention to. These issues could impact BAYRY stock value and guide investment decisions.

Mapping the Future of Biopharma: Insights from McKinsey's Helix Report

Explore the McKinsey Helix Report and discover insights into the future success of the biopharmaceutical industry.

IPO Outlook: BIAF, HPCO, WLDS

The week ahead's IPOs previewed here are bioAffinity Technologies (NASDAQ: BIAF), Hempacco (NASDAQ: HPCO) and Wearable Devices (NASDAQ: WLDS).

Daily Stock Watch: Figs (NYSE: FIGS) Stock Slips

After a short-lived rally, the Figs (NYSE: FIGS) stock price dips. Is FIGS stock a good long-term investment?

Daily Stock Watch: EAR Stock Rockets by 120%

Hearing aid company Eargo Inc (NASDAQ: EAR) has seen its share price soar in the latest chapter of a topsy turvy year for the business. But is EAR stock a good investment?

Bausch + Lomb IPO: A Good Investment?

Bausch + Lomb is about to go public with an IPO, so we're taking a look at the stock to see if there's a clear case for investing.

SRRA Shares Higher: Sierra Oncology Cancer Drug Shines in Testing

Sierra Oncology (NASDAQ: SRRA) shares leapt by more than 25% on Wednesday after a breakthrough in the firm's quest to commercialize a blood cancer treatment.

Investing in Shroom Stocks

Shroom stocks are increasingly popular and the upside potential is huge. Here's an overview of the sector and a list of stocks available.

Is Pfizer a Good Investment?

Pfizer offers a lot more to shareholders than a boost from COVID-19 vaccine revenues. With growth potential ahead, it may be undervalued.